Versor Investments LP Takes Position in TransMedics Group, Inc. $TMDX

Key Points

• Versor Investments LP acquired a new stake in TransMedics Group, purchasing 7,476 shares valued at approximately $503,000 during the first quarter.
• TransMedics Group reported a 37.7% increase in quarterly revenue year-over-year, reaching $157.37 million and exceeding analyst estimates.
• Wall Street analysts are optimistic about TransMedics, with multiple upgrades in price targets, projecting a consensus price target of $123.00 and an average rating of "Moderate Buy."

Versor Investments LP acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 7,476 shares of the company's stock, valued at approximately $503,000.

A number of other hedge funds also recently modified their holdings of TMDX. NBC Securities Inc. bought a new stake in shares of TransMedics Group in the 1st quarter worth approximately $25,000. Hager Investment Management Services LLC lifted its position in shares of TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after acquiring an additional 205 shares during the period. CWM LLC lifted its position in shares of TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after acquiring an additional 155 shares during the period. GAMMA Investing LLC lifted its position in shares of TransMedics Group by 551.7% in the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after acquiring an additional 1,324 shares during the period. Finally, Sava Infond d.o.o. lifted its position in shares of TransMedics Group by 46.7% in the 1st quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock worth $148,000 after acquiring an additional 700 shares during the period. Institutional investors own 99.67% of the company's stock.

Insiders Place Their Bets

In related news, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the sale, the director directly owned 2,866 shares of the company's stock, valued at $362,405.70. This trade represents a 63.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider directly owned 13,955 shares of the company's stock, valued at $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.00% of the company's stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of research reports. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Wall Street Zen upgraded TransMedics Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Piper Sandler restated an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Morgan Stanley raised their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Finally, Canaccord Genuity Group raised their target price on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $123.00.

TransMedics Group Price Performance

Shares of TransMedics Group stock traded up $1.04 during midday trading on Friday, hitting $119.85. 1,032,110 shares of the company were exchanged, compared to its average volume of 1,241,494. The firm has a 50 day simple moving average of $121.65 and a 200-day simple moving average of $101.51. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The firm has a market cap of $4.09 billion, a P/E ratio of 62.10 and a beta of 2.09. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same period last year, the firm posted $0.35 EPS. The business's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. Research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.